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 Canine osteoarthritis (OA) is an irreversible chronic condition affecting 1 
in every 5 adult dogs1. It is characterized by inflammation and the gradual 
breakdown of joint structures, followed by pain and decreased mobility of the 
affected area2. Treatment strategies aim to slow the progression of disease 
and decrease the associated pain and inflammation.  
 The cyclooxygenase (COX) enzyme, specifically the COX-2 isoform, is 
suggested to be involved in the pathogenesis of OA. Various drugs such as 
non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the COX enzymes, 
thereby decreasing inflammation and providing analgesia3. 
 The NSAID meloxicam, a COX-2 selective inhibitor, is commonly used 
to treat OA cases, and is associated with fewer adverse effects relative to 
other NSAIDs2. Frequently administered as an oral suspension, this mode of 
delivery poses various challenges including decreased owner compliance and 
reduced tolerance in some dogs. Recently, transdermal delivery systems have 
been suggested with advantages such as; better patient compliance, 
consistent and controllable drug levels, and localized drug delivery with 
reduced systemic levels of drug4.  
 In 2009, Yuan et al.5 demonstrated that higher levels of meloxicam were 
achieved in synovial fluid compared to the plasma of beagle dogs when 
treated with a gel form of meloxicam that was topically applied to the stifle 
joint. They also showed that this ratio was higher than that achieved with an 
oral meloxicam pill.  
 In this study, meloxicam compounded in delivra® is being investigated 
for use in veterinary medicine as an alternative to currently available 
meloxicam dosage forms. Meloxicam is administered to healthy research dogs 
as a clinically approved oral suspension (Metacam®) or compounded in a 
transdermal delivery system (delivra®). Levels of meloxicam in plasma and 
synovial fluid are compared between the two delivery systems. Additionally, 
any adverse systemic or local effects on the skin tissue are compared.  
 Dogs were randomized to either oral or topical meloxicam groups in phase 1, then crossed over in phase 2 
after a 21-day washout period, as shown above. Dogs were also randomized to either left or right stifle joint for 
sample collection in phase 1, with the remaining stifle joint used for sample collection in phase 2. 
 Metacam® and delivra® were given once daily for 6 days, as shown below. After treatment assignment, 
dogs were randomized to group 1 or 2. Group 1 dogs began treatment on day 1, Group 2 dogs began treatment 
on day 2. A loading dose of meloxicam was administered on day 1 in the Metacam® treatment group. 
 Daily assessments were performed on temperature, weight, respiration rate, pulse and behavior of every 
dog. 
 Drug stability study 
 Investigate the effects of various storage conditions on the shelf life 
and distribution of meloxicam compounded in the delivra® carrier system. 
Conditions include varying: 
•  Temperatures 
•  Light sources 
•  Freeze-thaw cycles 
Rat paw edema study  
 Investigate the effects of topically applied meloxicam in delivra® on 
the carrageenan-induced paw edema model of inflammation in rats. 
 Synovial fluid and plasma sample analyses for meloxicam 
concentration are currently being conducted. In addition, analyses of skin 
biopsy samples for local adverse effects are currently being conducted. 
 Biochemical analyses of plasma and urine samples demonstrated 
no systemic adverse effects with topical or oral administration of 
meloxicam. Daily assessments of temperature, respiration rate, pulse, 
weight and behavior for each dog were similar between oral and topical 
meloxicam treatment groups. 
 It is expected that: 
i)  Topically applied meloxicam using delivra® will achieve equal or 
higher synovial fluid drug levels in the stifle compared to orally 
administered Metacam® 
ii)  Topically applied meloxicam using delivra® will achieve lower plasma 
drug levels compared to orally administered Metacam®  
iii)  Topically applied meloxicam using delivra® will result in fewer adverse 
effects compared to orally administered Metacam® 
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delivra® 
•  Daily dose: 1.0 mg meloxicam/kg 
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Baseline samples: 
•  Plasma 
­  meloxicam concentration 
•  Synovial fluid 
­  cytological slide 
­  meloxicam concentration 
•  2 stifle skin biopsies 
­  histological analysis 
Post-treatment samples: 
•  Plasma 
­  meloxicam concentration 
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­  complete blood cell count 
•  Synovial fluid 
­  cytological slide 
­  meloxicam concentration 
•  2 stifle skin biopsies 
­  histological analysis 
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­  biochemical profile 
­  complete blood cell 
count 
•  Urine 
•  Weight 
•  Subjective clinical 
assessment 
Sample collection  
